A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
← catalyst calendarNCT06208878 · readout ≤ 4,395 d
Sponsored by CRISPR Therapeutics AG (industry) · CRSP — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
70estimated
Sites
22
Countries
Australia, Canada, Germany +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-22 | actual | When the study began enrolling |
| Primary completion | Aug 2038 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2038 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hematologic Malignancy
- Solid Malignancy
Intervention
- Other: Non Interventional
Primary outcome
what the primary-completion date above is the date OFThe incidence of adverse events, serious adverse events and adverse events of special interest related to CRISPR CAR T cellular therapy treatment.
measured 15 years
Permalink · CRSP's whole pipeline · Catalyst calendar · Every registered study · What changed